Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Pain 1Ovarian Neoplasms 1Neoplasms 1Multi-organ Metastatic Colorectal Cancer 1Lymphatic Metastasis 1Cholangiocarcinoma 1Carcinoma, Medullary 1Breast Neoplasms 1Agnosia 1

Interventions

pembrolizumab 24Carboplatin 21Paclitaxel 20olaparib 19Magnetic Resonance Spectroscopy 14Bevacizumab 14Cyclophosphamide 12Specimen Handling 11Nivolumab 11Gemcitabine 11Taxes 10niraparib 8Cisplatin 8Biopsy 8liposomal doxorubicin 7fludarabine 7Surveys and Questionnaires 6Immunoglobulin G 6Doxorubicin 6Disulfides 6durvalumab 5palbociclib 4oregovomab 4X-Rays 4Ipilimumab 4mirvetuximab soravtansine 3ipatasertib 3defactinib 3cediranib 3atezolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Ovarian Neoplasms × Radiofrequency Ablation × Clear all
NCT02487693 2016-02-23

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma

The First People's Hospital of Changzhou

Phase 2 Active not recruiting
50 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡